|
1.
|
|
8 p, 1.2 MB |
AXL - a new player in resistance to HER2 blockade
/
Adam-Artigues, Anna (INCLIVA Biomedical Research Institute) ;
Arenas, Enrique J (Centro de Investigación Biomédica en Red de Cáncer) ;
Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Prat, Aleix (SOLTI Breast Cancer Research Group) ;
Cejalvo, Juan Miguel (Vall d'Hebron Institut d'Oncologia)
HER2 is a driver in solid tumors, mainly breast, oesophageal and gastric cancer, through activation of oncogenic signaling pathways such as PI3K or MAPK. HER2 overexpression associates with aggressive disease and poor prognosis. [...]
2023 -  10.1016/j.ctrv.2023.102639
Cancer Treatment Reviews, Vol. 121 (december 2023) , p. 102639
|
|
|
2.
|
|
13 p, 3.0 MB |
Defining the optimal sequence for the systemic treatment of metastatic breast cancer
/
Albanell Mestres, Joan (Hospital del Mar (Barcelona, Catalunya)) ;
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez, Leticia C. (Complejo Hospitalario Universitario de A Coruña) ;
López-Muñiz, José Ignacio Chacón (Hospital Virgen de la Salud (Toledo)) ;
Ciruelos, Eva (Hospital 12 de Octubre (Madrid)) ;
de Juan Ferre, Ana (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
del Barco Berrón, S. (Institut Català d'Oncologia) ;
Pérez, Y.F. (Hospital Universitario Central de Asturias) ;
Mata, J.G. (Hospital Santa María Nai en Ourense) ;
Palomo, A.G. (Complejo Asistencial de León) ;
Gregori, J.G. (Fundació Institut Valencià d'Oncologia) ;
Pardo, P.G. (Hospital Universitari Vall d'Hebron) ;
Mañas, J.J.I. (Complejo Hospitalario de Navarra) ;
Hernández, A.L. (Hospital Clínic Universitari (València)) ;
de Dueñas, E.M. (Consorci Hospitalari Provincial de Castelló) ;
Jáñez, N.M. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Murillo, S.M. (Hospital Universitari Arnau de Vilanova) ;
Bofill, J.S. (Hospital Universitario Nuestra Señora de Valme) ;
Auñón, P.Z. (Hospital Universitario La Paz (Madrid)) ;
Sanchez-Rovira, P. (Complejo Hospitalario de Jaén) ;
Universitat Autònoma de Barcelona
Metastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing number of therapeutic options makes it difficult to determine the best choice in each particular situation. [...]
2017 - 10.1007/s12094-016-1520-2
Clinical & Translational Oncology, Vol. 19 Núm. 2 (january 2017) , p. 149-161
|
|
|
3.
|
|
|
4.
|
|
13 p, 904.0 KB |
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma : data from the AGAMENON-SEOM registry
/
Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias. ISPA) ;
Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Martinez-Torron, Alba (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Custodio, Ana (Hospital Universitario La Paz (Madrid)) ;
Serra, Olbia (Institut Català d'Oncologia) ;
Cacho Lavin, Diego (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ;
Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sauri, Tamara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
López, Flora (Hospital Universitario 12 de Octubre (Madrid)) ;
Visa, Laura (Hospital Universitario El Mar) ;
Granja, Mónica (Hospital Universitario Clínico San Carlos (Madrid)) ;
Martínez Lago, Nieves (Complejo Hospitalario Universitario de A Coruña) ;
Arrazubi, Virginia (Instituto de Investigación Sanitaria de Navarra) ;
Vidal Tocino, Rosario (Complejo Asistencial Universitario de Salamanca-IBSAL) ;
Hernandez, Raquel (Hospital Universitario de Canarias (La Laguna)) ;
Aguado, Gema (Hospital General Universitario Gregorio Marañón) ;
Cano, Juana María (Hospital General Universitario de Ciudad Real) ;
Martín Carnicero, Alfonso (Hospital San Pedro de Alcántara) ;
Mangas, Montserrat (Hospital de Galdakao (Usansolo, Biscaia)) ;
Pimentel, Paola (Hospital General Universitario Santa Lucía (Cartagena, Múrcia)) ;
Fernández Montes, Ana (Complejo Hospitalario de Orense) ;
Macias Declara, Ismael (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Longo, Federico (Hospital Universitario Ramón y Cajal (Madrid)) ;
Ramchandani, Avinash (Hospital Universitario Insular de Gran Canaria) ;
Martín-Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Hurtado, Alicia (Hospital Universitario Fundación Alcorcón) ;
Azkárate, Aitor (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Hernández Pérez, Carolina (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife)) ;
Serrano, Raquel (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Gallego, Javier (Hospital General Universitario de Elche)
Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. [...]
2021 - 10.1177/17588359211019672
Therapeutic Advances in Medical Oncology, Vol. 13 (2021)
|
|
|
5.
|
|
14 p, 445.0 KB |
Targeting HER2 in non-small-cell lung cancer (NSCLC) : a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
/
Riudavets, M. (Department of Cancer Medicine. Gustave Roussy Cancer Campus) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Abdayem, P. (Department of Cancer Medicine. Gustave Roussy Cancer Campus) ;
Planchard, D. (Department of Cancer Medicine. Gustave Roussy Cancer Campus)
Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms, i. e. gene mutation (1%-4% of cases), gene amplification (2%-5%) and protein overexpression (2%-30%), with different prognostic and predictive outcomes. [...]
2021 - 10.1016/j.esmoop.2021.100260
ESMO open, Vol. 6 Núm. 5 (october 2021) , p. 100260
|
|
|
6.
|
|
19 p, 9.6 MB |
Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation
/
Gámez-Chiachio, Manuel (Centro de Investigación Biomédica en Red de Cáncer) ;
Molina-Crespo, Ángela (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Ramos-Nebot, Carmen (Centro de Investigación Biomédica en Red de Cáncer) ;
Martinez-Val, Jeannette (Universidade de Santiago de Compostela) ;
Martinez, Lidia (Universidad Autónoma de Madrid) ;
Gassner, Katja (Mecanismos Moleculares Y Terapia Experimental en Oncologia-Programa OncobellIdibell (L'Hospitalet de Llobregat)) ;
Llobet, Francisco J. (Mecanismos Moleculares Y Terapia Experimental en Oncologia-Programa OncobellIdibell (L'Hospitalet de Llobregat)) ;
Soriano, Mario (Centro de Investigación Príncipe Felipe (València)) ;
Hernandez, Alberto (Centro de Investigación Príncipe Felipe (València)) ;
Cordani, Marco (Universidad Autónoma de Madrid) ;
Bernadó Morales, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Diaz, Eva (Fundación MD Anderson Internacional (Madrid)) ;
Rojo-Sebastian, Alejandro (Fundación MD Anderson Internacional (Madrid)) ;
Triviño, Juan Carlos (Sistemas Genómicos) ;
Sánchez-García, Laura (Mecanismos Moleculares Y Terapia Experimental en Oncologia-Programa OncobellIdibell (L'Hospitalet de Llobregat)) ;
Rodríguez-Barrueco, Ruth (Universitat de Barcelona. Unitat d'Anatomia Humana i Embriologia) ;
Arribas, Joaquín V (Vall d'Hebron Institut d'Oncologia) ;
Llobet-Navás, David (Mecanismos Moleculares Y Terapia Experimental en Oncologia-Programa OncobellIdibell (L'Hospitalet de Llobregat)) ;
Sarrió, David (Centro de Investigación Biomédica en Red de Cáncer) ;
Moreno-Bueno, Gema (Fundación MD Anderson Internacional (Madrid)) ;
Universitat Autònoma de Barcelona
Gasdermin B (GSDMB) over-expression promotes poor prognosis and aggressive behavior in HER2 breast cancer by increasing resistance to therapy. Decoding the molecular mechanism of GSDMB-mediated drug resistance is crucial to identify novel effective targeted treatments for HER2/GSDMB aggressive tumors. [...]
2022 - 10.1186/s13046-022-02497-w
Journal of Experimental & Clinical Cancer Research : CR, Vol. 41 (september 2022)
|
|
|
7.
|
|
14 p, 1.4 MB |
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer : a pilot clinical trial
/
Quintela-Fandino, Miguel (Hospital Universitario Quiron. Medical Oncology Department) ;
Holgado, Esther (Hospital Universitario Ramón y Cajal (Madrid)) ;
Manso, Luis (Hospital Universitario 12 de Octubre (Madrid)) ;
Morales, Serafin (Hospital Arnau de Vilanova (València)) ;
Bermejo, Begoña (Centro de Investigación Biomédica en Red de Cáncer) ;
Colomer, Ramon (Universidad Autónoma de Madrid. Facultad de Medicina) ;
Apala, Juan V. (Hospital Universitario de Fuenlabrada ( Madrid)) ;
Blanco, Raquel (Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology) ;
Muñoz, Manuel (Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center) ;
Caleiras, Eduardo (Histopathology Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center) ;
Iranzo, Vega (Universitat de València. Departament de Medicina) ;
Martínez López, Mario (Hospital Universitario 12 de Octubre (Madrid)) ;
Dominguez, Orlando (Genomics Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center) ;
Hornedo, Javier (Hospital Universitario Quiron. Medical Oncology Department) ;
Gonzalez-Cortijo, Lucia (Hospital Universitario Quiron. Medical Oncology Department) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Gasol Cudos, Ariadna (Hospital Arnau de Vilanova (València)) ;
Malon, Diego (Hospital Universitario de Fuenlabrada ( Madrid)) ;
Lopez-Alonso, Antonio (Spanish National Cancer Research Center) ;
Moreno-Ortíz, María C. (Centro Nacional de Biotecnología/CSIC) ;
Mouron, Silvana (Spanish National Cancer Research Center) ;
Mañes, Santos (Centro Nacional de Biotecnología/CSIC) ;
Universitat Autònoma de Barcelona
Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. [...]
2020 - 10.1186/s13058-020-01362-y
Breast cancer research, Vol. 22 (november 2020)
|
|
|
8.
|
|
10 p, 1.3 MB |
Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy
/
Floros, Konstantinos V. (Philips Institute for Oral Health Research) ;
Lochmann, Timothy L. (Philips Institute for Oral Health Research) ;
Hu, Bin (Virginia Commonwealth University School of Medicine) ;
Monterrubio, Carles (Memorial Sloan Kettering Cancer Center) ;
Hughes, Mark T. (Philips Institute for Oral Health Research) ;
Wells, Jason D. (Norris Cotton Cancer Center) ;
Bernadó Morales, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Ghotra, Maninderjit S. (Philips Institute for Oral Health Research) ;
Costa, Carlotta (Massachusetts General Hospital (Boston)) ;
Souers, Andrew J. (AbbVie Inc) ;
Boikos, Sosipatros A. (Virginia Commonwealth University) ;
Leverson, Joel D. (AbbVie Inc) ;
Tan, Ming (University of South Alabama) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ;
Koblinski, Jennifer E. (Virginia Commonwealth University School of Medicine) ;
Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Paré Brunet, Laia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Miller, Todd W. (Norris Cotton Cancer Center) ;
Dozmorov, Mikhail G. (Virginia Commonwealth University) ;
Harada, Hisashi (Philips Institute for Oral Health Research) ;
Windle, Brad E. (Philips Institute for Oral Health Research) ;
Scaltriti, Maurizio (Memorial Sloan Kettering Cancer Center) ;
Faber, Anthony C. (Philips Institute for Oral Health Research)
In HER2 -amplified breast cancers, HER2 inhibitors have been very successful as adjuvant therapy but not as monotherapy. Here, we demonstrate that coamplification of a HER2 intronic miRNA causes intrinsic resistance to HER2 inhibitors by indirectly down-regulating the pro-apoptotic NOXA. [...]
2018 - 10.1073/pnas.1717820115
Proceedings of the National Academy of Sciences of the United States of America, Vol. 115 (february 2018) , p. E2594-E2603
|
|
|
9.
|
|
16 p, 2.3 MB |
Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer
/
Palomeras, Sònia (Universitat de Girona. Departament de Ciències Mèdiques) ;
Diaz-Lagares, Angel (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Viñas, Gemma (Institut d'Investigació Biomèdica de Girona) ;
Setien, Fernando (Hospital Universitari de Bellvitge) ;
Ferreira, Humberto J. (Hospital Universitari de Bellvitge) ;
Oliveras, Glòria (Hospital Universitari de Girona Doctor Josep Trueta) ;
Crujeiras, Ana B. (Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición) ;
Hernández, Alejandro (Institut Català d'Oncologia) ;
Lum, David H. (University of Utah. Huntsman Cancer Institute) ;
Welm, Alana L. (University of Utah. Huntsman Cancer Institute) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Puig, Teresa (Universitat de Girona. Departament de Ciències Mèdiques) ;
Universitat Autònoma de Barcelona
Background: Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology. [...]
2019 - 10.1186/s13058-019-1160-x
Breast cancer research, Vol. 21 Núm. 1 (may 2019) , p. 79
|
|
|
10.
|
|
14 p, 3.0 MB |
The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1
/
Nadal-Serrano, Mercedes (Vall d'Hebron Institut d'Oncologia) ;
Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ;
Escrivá-de-Romaní, Santiago (Hospital Universitari Vall d'Hebron) ;
Bernadó Morales, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Luque, Antonio (Vall d'Hebron Institut d'Oncologia) ;
Escorihuela, Marta (Vall d'Hebron Institut d'Oncologia) ;
Espinosa-Bravo, Martín (Hospital Universitari Vall d'Hebron) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Dijcks, Fred A. (Preclinical R&D, The Netherlands) ;
Dokter, Wim H. A. (Preclinical R&D, The Netherlands) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Saura, Cristina (Hospital Universitari Vall d'Hebron) ;
Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ;
Universitat Autònoma de Barcelona
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. [...]
2020 - 10.3390/cancers12030670
Cancers, Vol. 12 (march 2020)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
